

Supplementary Material File 4: Data tables for NMAs

Table 1: Data table for the RCTs included in the NMA for overall survival

Study	Intervention	Patients Randomised, N	Relative effect (lnHR)	SE(lnHR)
Aikata (2006) ¹	RFA	23	-0.197	0.654
	RFA + TACE	21		
Brunello (2008) ²	RFA	70	0.198	0.275
	PEI	69		
Chen (2014) ³	RFA	68	-0.689	0.241
	RFA + Iodine-125	68		
Fang (2014) ⁴	RFA	60	0.342	0.278
	Resection	60		
Ferrari (2007) ⁵	RFA	16	0.378	0.294
	Laser	12		
Giorgio (2011) ⁶	RFA	142	0.211	0.282
	PEI	143		
Huang (2010) ⁷	RFA	88	-0.987	0.440
	Resection	71		
Huo (2003) ⁸	PAI	31	0.039	0.360
	TACE + PAI	24		
Koda (2001) ⁹	PEI	26	-0.356	0.462
	TACE + PEI	26		
Lin (2005) ^{*10}	RFA	62	--	0.029**
	PEI	62	0.384	0.169
	PAI	63	0.599	0.342
Liu (2016) ¹¹	Resection	66	0.390	0.274
	RFA + TACE	69		
Ng (2017) ¹²	RFA	26	-0.070	0.418
	Resection	29		
Shibata (2009) ¹³	RFA	43	-0.434	0.580
	RFA + TACE	46		
Shiina (2005) ¹⁴	RFA	118	0.634	0.252
	PEI	114		
Vietti Violi (2018) ¹⁵	RFA	76	-0.067	0.400
	MWA	76		
Zhang (2007) ¹⁶	RFA	31	-0.106	0.577
	RFA + PEI	29		

* For the three-armed study Lin (2005), the lnHRs and the corresponding standard errors included in the table are compared to the baseline treatment, RFA. **This is the covariance between the reported lnHRs.

Abbreviations: HR: hazard ratio, SE: standard error

Table 2: Data table for the RCTs included in the NMA for progression-free survival

Study	Intervention	Patients Randomised, N	Relative effect (lnHR)	SE(lnHR)
Fang (2014) ⁴	RFA	60	0.193	0.251
	Resection	60		
Izumi (2019) ^{†17}	RFA	148	-0.039	0.147
	Resection	145		
Lenicioni (2003) ¹⁸	RFA	54	0.653	0.277
	PEI	50		
Lin (2005) ^{*10}	RFA	62	--	0.011**
	PEI	62	0.254	0.111
	PAI	63	0.438	0.225
Ng (2017) ¹²	RFA	26	-0.038	0.339
	Resection	29		
Shibata (2009) ¹³	RFA	43	-0.228	0.303
	RFA + TACE	46		

* For the three-armed study Lin (2005), difference in lnHR and the corresponding standard error included in the table is compared to the baseline treatment, RFA. **This is the covariance for the baseline treatment (RFA). † The N for Izumi (2019) was reported as the number of patients analysed, and not the number randomised.

Abbreviations: HR: Hazard Ratio, SE: standard error

Table 3: Data table for RCTs included in the NMA for overall recurrence

Study	Intervention	Patients Randomised, N	Relative effect (lnRR)	SE(lnRR)
Chen (2014) ³	RFA	68	-0.368	0.185
	RFA + Iodine-125	68		
Fang (2014) ⁴	RFA	60	-0.047	0.244
	Resection	60		
Gan (2004) ¹⁹	RFA	18	-0.629	0.522
	RFA + Systemic Chemotherapy	20		
Huang (2005) ²⁰	PEI	40	-0.182	0.265
	Resection	42		
Mizuki (2010) ²¹	PEI	14	0.169	0.206
	TACE + PEI	16		
Shiina (2005) ¹⁴	RFA	118	0.178	0.082
	PEI	114		
Yan (2016) ²²	Resection	60	0.738	0.318
	MWA + Sorafenib	60		

Abbreviations: RR: Relative Risk, SE: standard error

Table 4: Data table for RCTs included in the NMA for local recurrence

Study	Intervention	Patients Randomised, N	Relative effect (lnRR)	SE(lnRR)
Aikata (2006) ¹	RFA	23	0.086	0.952
	RFA + TACE	21		
Chen (2005) ²³	RFA	68	-0.511	0.488
	RFA + PEI	68		
Giorgio (2011) ⁶	RFA	142	-0.104	0.323
	PEI	143		
Koda (2001) ⁹	PEI	26	-1.012	0.518
	TACE + PEI	26		
Lenicioni (2003) ¹⁸	RFA	54	-1.543	0.627
	PEI	50		
Lin (2004) ^{*24}	RFA	37	--	0.173**
	PEI	38	0.668	0.498
	High Dose PEI	39	0.536	0.508
Lin (2005) ^{*10}	RFA	62	--	0.110**
	PEI	62	0.865	0.382
	PAI	63	0.738	0.391
Orlachhio (2014) ²⁵	RFA	15	1.099	0.729
	Laser Ablation	15		
Shibata (2009) ¹³	RFA	43	0.220	0.497
	RFA + TACE	46		
Vietti Violi (2018) ¹⁵	RFA	76	0.482	0.456
	MWA	76		

* For the three-armed studies Lin (2004) and Lin (2005), differences in lnRR and their corresponding standard errors included in the table are compared to the baseline treatment, RFA. **These numbers are the covariance for the baseline treatment (RFA).

Abbreviations: RR: relative risk, SE: standard error

Table 5: Data table for non-randomised studies included in the updated NMA for overall survival

Study	Intervention	Patients Included, N	Relative effect (lnHR)	SE(lnHR)
Huang (2014) ²⁶	RFA	121	0.117	0.287
	Resection	225		
Leeds Hospital Data (Dr Tze Wah, Leeds Teaching Hospitals NHS Trust, personal communication 5th October 2021)	RFA	201	--	0.014**
	MWA	188	-0.153	0.195
	IRE	19	0.040	0.424

* For the three-armed study Leeds Hospital Data, the lnHRs and the corresponding standard errors included in the table are compared to the baseline treatment, RFA. **This is the covariance between the reported lnHRs.

Abbreviations: HR: hazard ratio, SE: standard error

Table 6: Data table for non-randomised studies included in the updated NMA for progression-free survival

Study	Intervention	Patients Included, N	Relative effect (lnHR)	SE(lnHR)
Huang (2014) ²⁶	RFA	121	-0.0994	0.2096
	Resection	225		
Qian (2012) ²⁷	RFA	20	0.06	0.76
	MWA	22		
Leeds Hospital Data* (Dr Tze Wah, Leeds Teaching Hospitals NHS Trust, personal communication 5th October 2021)	RFA	201	--	0.011**
	MWA	188	-0.110	0.154
	IRE	19	0.104	0.349

* For the three-armed Leeds Hospital data, difference in lnHR and the corresponding standard error included in the table is compared to the baseline treatment, RFA. **This is the covariance for the baseline treatment (RFA).

Abbreviations: HR: hazard ratio, SE: standard error

Table 7: Data table for non-randomised studies included in the updated NMA for local recurrence

Study	Intervention	Patients Included, N	Relative effect (lnRR)	SE(lnRR)
Leeds Hospital Data* (Dr Tze Wah, Leeds Teaching Hospitals NHS Trust, personal communication 5th October 2021)	RFA	201	--	0.076**
	MWA	188	-0.059	0.280
	IRE	19	0.946	0.393

* For the three-armed Leeds Hospital data, differences in lnRR and their corresponding standard errors included in the table are compared to the baseline treatment, RFA. **This is the covariance for the baseline treatment (RFA).

Abbreviations: RR: relative risk, SE: standard error

References

- 1 Aikata, H. *et al.* Radiofrequency ablation combined with transcatheter arterial chemoembolization for small hepatocellular carcinomas. *Hepatology* **44**, 494A (2006).
- 2 Brunello, F. *et al.* Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. *Scand J Gastroenterol* **43**, 727-735, doi:<https://dx.doi.org/10.1080/00365520701885481> (2008).
- 3 Chen, K. *et al.* Increased survival in hepatocellular carcinoma with iodine-125 implantation plus radiofrequency ablation: a prospective randomized controlled trial. *J Hepatol* **61**, 1304-1311, doi:<https://dx.doi.org/10.1016/j.jhep.2014.07.026> (2014).
- 4 Fang, Y. *et al.* Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. *J Gastroenterol Hepatol* **29**, 193-200, doi:<https://dx.doi.org/10.1111/jgh.12441> (2014).
- 5 Ferrari, F. S. *et al.* Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long-term results. *Radiol Med* **112**, 377-393 (2007).
- 6 Giorgio, A. *et al.* Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. *Anticancer Res* **31**, 2291-2295 (2011).
- 7 Huang, J. *et al.* A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. *Ann Surg* **252**, 903-912, doi:<https://dx.doi.org/10.1097/SLA.0b013e3181efc656> (2010).
- 8 Huo, T. I. *et al.* Sequential transarterial chemoembolization and percutaneous acetic acid injection therapy versus repeated percutaneous acetic acid injection for unresectable hepatocellular carcinoma: a prospective study. *Ann Oncol* **14**, 1648-1653 (2003).
- 9 Koda, M. *et al.* Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. *Cancer* **92**, 1516-1524 (2001).

- 10 Lin, S. M., Lin, C. J., Lin, C. C., Hsu, C. W. & Chen, Y. C. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. *Gut* **54**, 1151-1156 (2005).
- 11 Liu, H. *et al.* Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. *Br J Surg* **103**, 348-356, doi:<https://dx.doi.org/10.1002/bjs.10061> (2016).
- 12 Ng, K. K. *et al.* Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. *Br J Surg* **104**, 1775-1784, doi:<https://dx.doi.org/10.1002/bjs.10677> (2017).
- 13 Shibata, T. *et al.* Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? *Radiology* **252**, 905-913, doi:<https://dx.doi.org/10.1148/radiol.2523081676> (2009).
- 14 Shiina, S. *et al.* A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. *Gastroenterology* **129**, 122-130 (2005).
- 15 Vietti, V. *et al.* Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. *Lancet Gastroenterol Hepatol* **3**, 317-325, doi:[https://dx.doi.org/10.1016/S2468-1253\(18\)30029-3](https://dx.doi.org/10.1016/S2468-1253(18)30029-3) (2018).
- 16 Zhang, Y. J. *et al.* Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. *Radiology* **244**, 599-607 (2007).
- 17 Izumi, N. *et al.* A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial). *J Clin Oncol* **37** (2019).
- 18 Lencioni, R. A. *et al.* Small hepatocellular carcinoma in cirrhosis: randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. *Radiology* **228**, 235-240 (2003).
- 19 Gan, Y. H. *et al.* [Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma]. *Zhonghua Zhong Liu Za Zhi* **26**, 496-498 (2004).
- 20 Huang, G. T. *et al.* Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. *Ann Surg* **242**, 36-42 (2005).
- 21 Mizuki, A. *et al.* Addition of transcatheter arterial chemoembolization decreased local recurrence but had no survival benefit to percutaneous ethanol injection therapy for patients with small hepatocellular carcinoma: a multicenter randomized control study. *Oncol Lett* **1**, 855-859 (2010).
- 22 Yan, S. Y. *et al.* The clinical effect and relevant mechanism of combined sorafenib and radiofrequency ablation in the treatment of early small hepatocellular carcinoma. *Oncol Lett* **12**, 951-955 (2016).
- 23 Chen, M. S. *et al.* [Randomized clinical trial of percutaneous radiofrequency ablation plus absolute ethanol injection compared with radiofrequency ablation alone for small hepatocellular carcinoma]. *Zhonghua Zhong Liu Za Zhi* **27**, 623-625 (2005).
- 24 Lin, S. M., Lin, C. J., Lin, C. C., Hsu, C. W. & Chen, Y. C. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. *Gastroenterology* **127**, 1714-1723 (2004).
- 25 Orlicchio, A. *et al.* Comparative evaluation of percutaneous laser and radiofrequency ablation in patients with HCC smaller than 4 cm. *Radiol Med* **119**, 298-308, doi:<https://dx.doi.org/10.1007/s11547-013-0339-y> (2014).
- 26 Huang, G. *et al.* Quality of life after surgical resection compared with radiofrequency ablation for small hepatocellular carcinomas. *Br J Surg* **101**, 1006-1015, doi:<https://dx.doi.org/10.1002/bjs.9539> (2014).
- 27 Qian, G. J. *et al.* Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellular carcinoma: experimental and clinical studies. *Eur Radiol* **22**, 1983-1990, doi:<https://dx.doi.org/10.1007/s00330-012-2442-1> (2012).